BACKGROUND: The purpose of this study is to determine the clinical outcomes associated with alternate listing transplantation, which utilizes "marginal" donor organs by transplanting them into high-risk recipients who fail to meet the standard criteria for transplantation. METHODS: The United Network for Organ Sharing provided de-identified patient-level data. Analysis focused on patients undergoing heart transplantation between January 1, 1999, and December 31, 2005 (n = 13,024). High-risk criteria included age more than 65 years old, retransplantation, hepatitis C-positive, human immunodeficiency virus-positive, creatinine clearance less than 30 mL/min, diabetes mellitus with peripheral vascular disease, and diabetes with creatinine clearance less than 40 mL/min. Marginal donor criteria included age more than 55 years, diabetes mellitus, hepatitis C-positive, human immunodeficiency virus-positive, ejection fraction less than 45%, and donor:recipient weight less than 0.7. RESULTS: Survival in the standard transplant group, defined as non-high-risk patients who received nonmarginal organs, was better than in all other groups (p < 0.001). Alternate listing transplantation patients had the worst survival (p < 0.001). The 5-year survival for the alternate listing transplantation group was 51.4%, compared with 75.1% in the standard transplant group; the standard transplant patients, with the lowest incidence of in-hospital infection (21.1%) and dialysis (7.1%), also had the best transplant hospitalization outcomes (p < 0.001). In contrast, alternate listing transplantation patients had the highest incidence of in-hospital infection (35.4%; p < 0.001). Length of stay during transplant hospitalization was also shortest in the standard transplant group (18.8 days; p < 0.001). CONCLUSIONS: Alternate listing transplantation is associated with greater morbidity and resource utilization compared with standard transplantation. However, this strategy offers a median survival of 5.2 years to patients who would otherwise be expected to live 1 year, and therefore, may be reasonably applied to expand the benefits of transplantation. Further studies examining the costs and quality of life related to this approach are needed.
BACKGROUND: The purpose of this study is to determine the clinical outcomes associated with alternate listing transplantation, which utilizes "marginal" donor organs by transplanting them into high-risk recipients who fail to meet the standard criteria for transplantation. METHODS: The United Network for Organ Sharing provided de-identified patient-level data. Analysis focused on patients undergoing heart transplantation between January 1, 1999, and December 31, 2005 (n = 13,024). High-risk criteria included age more than 65 years old, retransplantation, hepatitis C-positive, human immunodeficiency virus-positive, creatinine clearance less than 30 mL/min, diabetes mellitus with peripheral vascular disease, and diabetes with creatinine clearance less than 40 mL/min. Marginal donor criteria included age more than 55 years, diabetes mellitus, hepatitis C-positive, human immunodeficiency virus-positive, ejection fraction less than 45%, and donor:recipient weight less than 0.7. RESULTS: Survival in the standard transplant group, defined as non-high-risk patients who received nonmarginal organs, was better than in all other groups (p < 0.001). Alternate listing transplantation patients had the worst survival (p < 0.001). The 5-year survival for the alternate listing transplantation group was 51.4%, compared with 75.1% in the standard transplant group; the standard transplant patients, with the lowest incidence of in-hospital infection (21.1%) and dialysis (7.1%), also had the best transplant hospitalization outcomes (p < 0.001). In contrast, alternate listing transplantation patients had the highest incidence of in-hospital infection (35.4%; p < 0.001). Length of stay during transplant hospitalization was also shortest in the standard transplant group (18.8 days; p < 0.001). CONCLUSIONS: Alternate listing transplantation is associated with greater morbidity and resource utilization compared with standard transplantation. However, this strategy offers a median survival of 5.2 years to patients who would otherwise be expected to live 1 year, and therefore, may be reasonably applied to expand the benefits of transplantation. Further studies examining the costs and quality of life related to this approach are needed.
Authors: H Laks; F G Scholl; D C Drinkwater; A Blitz; M Hamilton; J Moriguchi; G Fonarow; J Kobashigawa Journal: J Heart Lung Transplant Date: 1997-07 Impact factor: 10.247
Authors: Mandeep R Mehra; Jon Kobashigawa; Randall Starling; Stuart Russell; Patricia A Uber; Jayan Parameshwar; Paul Mohacsi; Sharon Augustine; Keith Aaronson; Mark Barr Journal: J Heart Lung Transplant Date: 2006-09 Impact factor: 10.247
Authors: G Michael Felker; Carmelo A Milano; Jonathan E E Yager; Adrian F Hernandez; Laura Blue; Michael B Higginbotham; Andrew J Lodge; Stuart D Russell Journal: J Heart Lung Transplant Date: 2005-08-08 Impact factor: 10.247
Authors: Jonathan M Chen; Mark J Russo; Kim M Hammond; Donna M Mancini; Aftab R Kherani; Jen M Fal; Pamela A Mazzeo; Sean P Pinney; Niloo M Edwards; Yoshifumi Naka Journal: Ann Thorac Surg Date: 2005-07 Impact factor: 4.330
Authors: Hillel Laks; Daniel Marelli; Gregg C Fonarow; Michele A Hamilton; Abbas Ardehali; Jaime D Moriguchi; Jessica Bresson; David Gjertson; Jon A Kobashigawa Journal: J Thorac Cardiovasc Surg Date: 2003-01 Impact factor: 5.209
Authors: Jonathan G Zaroff; Bruce R Rosengard; William F Armstrong; Wayne D Babcock; Anthony D'Alessandro; G William Dec; Niloo M Edwards; Robert S Higgins; Valluvan Jeevanandum; Myron Kauffman; James K Kirklin; Stephen R Large; Daniel Marelli; Tammie S Peterson; W Steves Ring; Robert C Robbins; Stuart D Russell; David O Taylor; Adrian Van Bakel; John Wallwork; James B Young Journal: Circulation Date: 2002-08-13 Impact factor: 29.690
Authors: Sean P Cleary; Robert Gryfe; Maha Guindi; Paul Greig; Lloyd Smith; Robert Mackenzie; Steven Strasberg; Sherif Hanna; Bryce Taylor; Bernard Langer; Steven Gallinger Journal: J Am Coll Surg Date: 2004-05 Impact factor: 6.113
Authors: Mark J Russo; David I Sternberg; Kimberly N Hong; Robert A Sorabella; Alan J Moskowitz; Annetine C Gelijns; Jessie R Wilt; Frank D'Ovidio; Steve M Kawut; Selim M Arcasoy; Joshua R Sonett Journal: Ann Thorac Surg Date: 2007-10 Impact factor: 4.330
Authors: Eno-Obong I Essien; Nehu Parimi; Jennifer Gutwald-Miller; Tyree Nutter; Thomas M Scalea; Deborah M Stein Journal: World J Surg Date: 2017-11 Impact factor: 3.352
Authors: Kimberly N Hong; Alexander Iribarne; Berhane Worku; Hiroo Takayama; Annetine C Gelijns; Yoshifumi Naka; Val Jeevanandam; Mark J Russo Journal: Ann Thorac Surg Date: 2011-06-17 Impact factor: 4.330
Authors: Scott R Auerbach; Marc E Richmond; Jonathan M Chen; Ralph S Mosca; Jan M Quaegebeur; Linda J Addonizio; Daphne T Hsu; Jacqueline M Lamour Journal: Pediatr Cardiol Date: 2011-09-04 Impact factor: 1.655
Authors: Robert A Sorabella; Halit Yerebakan; Ryan Walters; Koji Takeda; Paolo Colombo; Melana Yuzefpolskaya; Ulrich Jorde; Donna Mancini; Hiroo Takayama; Yoshifumi Naka Journal: Ann Thorac Surg Date: 2014-12-10 Impact factor: 4.330
Authors: P Christian Schulze; Jeffrey Jiang; Jonathan Yang; Faisal H Cheema; Kenneth Schaeffle; Tomoko S Kato; Maryjane Farr; Susan Restaino; Mario Deng; Mathew Maurer; Evelyn Horn; Farhana Latif; Paolo C Colombo; Ulrich Jorde; Nir Uriel; Jennifer Haythe; Rachel Bijou; Ron Drusin; Sun Hi Lee; Hiroo Takayama; Yoshifumi Naka; Donna M Mancini Journal: Circ Heart Fail Date: 2013-03-15 Impact factor: 8.790
Authors: R A Sorabella; L Guglielmetti; A Kantor; E Castillero; H Takayama; P C Schulze; D Mancini; Y Naka; I George Journal: Transplant Proc Date: 2015-12 Impact factor: 1.066
Authors: Imogen K Thomson; Brenda M Rosales; Patrick J Kelly; Kate Wyburn; Karen M J Waller; Daniel Hirsch; Michael J O'Leary; Angela C Webster Journal: Transplant Direct Date: 2019-10-17